Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor... Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic HNSCC excluding HPV-positive patients with oropharyngeal squamous cell carcinoma late in the fourth quarter of 2024 or early in the first quarter of 2025. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.57 | 20.8773354996 | 12.31 | 14.88 | 11.765 | 271533 | 12.93969784 | CS |
| 4 | 2.56 | 20.7792207792 | 12.32 | 14.88 | 11.64 | 335401 | 12.92396513 | CS |
| 12 | -4.64 | -23.7704918033 | 19.52 | 20.7087 | 11.1 | 449472 | 14.95199043 | CS |
| 26 | -11.37 | -43.3142857143 | 26.25 | 28.09 | 11.1 | 409985 | 18.48901397 | CS |
| 52 | -11.37 | -43.3142857143 | 26.25 | 28.09 | 11.1 | 409985 | 18.48901397 | CS |
| 156 | -11.37 | -43.3142857143 | 26.25 | 28.09 | 11.1 | 409985 | 18.48901397 | CS |
| 260 | -11.37 | -43.3142857143 | 26.25 | 28.09 | 11.1 | 409985 | 18.48901397 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
